Almut Scherer
Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry.
Ciurea A, Götschi A, Bräm R, Bürki K, Exer P, Andor M, Nissen M, Möller B, Hügle T, Rubbert-Roth A, Kyburz D, Distler O, Scherer A, Micheroli R. Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry. RMD Open 2023; 9
01.12.2023Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry.
01.12.2023RMD Open 2023; 9
Ciurea Adrian, Götschi Andrea, Bräm René, Bürki Kristina, Exer Pascale, Andor Michael, Nissen Michael J, Möller Burkhard, Hügle Thomas, Rubbert-Roth Andrea, Kyburz Diego, Distler Oliver, Scherer Almut, Micheroli Raphael
Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care.
Riek M, Scherer A, Möller B, Ciurea A, Von Mühlenen I, Gabay C, Kyburz D, Brulhart L, von Kempis J, Mueller R, Hasler P, Strahm T, von Känel S, Zufferey P, Dudler J, Finckh A. Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care. Sci Rep 2023; 13:17776.
18.10.2023Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care.
18.10.2023Sci Rep 2023; 13:17776
Riek Myriam, Scherer Almut, Möller Burkhard, Ciurea Adrian, Von Mühlenen Ines, Gabay Cem, Kyburz Diego, Brulhart Laure, von Kempis Johannes, Mueller Ruediger B, Hasler Paul, Strahm Tanja, von Känel Sabine, Zufferey Pascal, Dudler Jean, Finckh Axel
Anaemia is associated with higher disease activity in axial spondyloarthritis but is not an independent predictor of spinal radiographic progression: data from the Swiss Clinical Quality Management Registry.
Micheroli R, Kissling S, Bürki K, Möller B, Finckh A, Nissen M, Exer P, Bräm R, Kyburz D, Rubbert-Roth A, Andor M, Baraliakos X, de Hooge M, Distler O, Scherer A, Ciurea A. Anaemia is associated with higher disease activity in axial spondyloarthritis but is not an independent predictor of spinal radiographic progression: data from the Swiss Clinical Quality Management Registry. Clin Rheumatol 2023; 42:2377-2385.
08.06.2023Anaemia is associated with higher disease activity in axial spondyloarthritis but is not an independent predictor of spinal radiographic progression: data from the Swiss Clinical Quality Management Registry.
08.06.2023Clin Rheumatol 2023; 42:2377-2385
Micheroli Raphael, Kissling Seraphina, Bürki Kristina, Möller Burkhard, Finckh Axel, Nissen Michael J, Exer Pascale, Bräm René, Kyburz Diego, Rubbert-Roth Andrea, Andor Michael, Baraliakos Xenofon, de Hooge Manouk, Distler Oliver, Scherer Almut, Ciurea Adrian
Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.
Amstad A, Papagiannoulis E, Scherer A, Rubbert-Roth A, Finckh A, Mueller R, Dudler J, Möller B, Villiger P, Schulz M, Kyburz D. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy. Rheumatology (Oxford) 2022; 62:89-97.
23.12.2022Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.
23.12.2022Rheumatology (Oxford) 2022; 62:89-97
Amstad Andrea, Papagiannoulis Eleftherios, Scherer Almut, Rubbert-Roth Andrea, Finckh Axel, Mueller Ruediger, Dudler Jean, Möller Burkhard, Villiger Peter M, Schulz Martin, Kyburz Diego
Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases.
Raptis C, Berger C, Ciurea A, Andrey D, Polysopoulos C, Lescuyer P, Maletic T, Riek M, Scherer A, von Loga I, Safford J, Lauper K, Möller B, Vuilleumier N, Finckh A, Rubbert-Roth A. Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases. Front Immunol 2022; 13:1016927.
13.10.2022Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases.
13.10.2022Front Immunol 2022; 13:1016927
Raptis Catherine E, Berger Christoph T, Ciurea Adrian, Andrey Diego O, Polysopoulos Christos, Lescuyer Pierre, Maletic Tanja, Riek Myriam, Scherer Almut, von Loga Isabell, Safford Judith, Lauper Kim, Möller Burkhard, Vuilleumier Nicolas, Finckh Axel, Rubbert-Roth Andrea
Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort
Ciurea A, Scherer A, Distler O, Kyburz D, Dan D, Müller A, Bräm R, Andor M, Rubbert-Roth A, Möller B, Micheroli R, von Loga I, Bürki K, Papagiannoulis E, Finckh A. Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis 2020; 80:238-241.
22.09.2020Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort
22.09.2020Ann Rheum Dis 2020; 80:238-241
Ciurea Adrian, Scherer Almut, Distler Oliver, Kyburz Diego, Dan Diana, Müller Angela, Bräm René, Andor Michael, Rubbert-Roth Andrea, Möller Burkhard, Micheroli Raphael, von Loga Isabell, Bürki Kristina, Papagiannoulis Eleftherios, Finckh Axel
Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort
Ciurea A, Weber U, Boonen A, Dougados M, van der Heijde D, Michel B, Nissen M, Müller R, Weiss B, Tamborrini G, Rufibach K, Stekhoven D, Kissling R, Beyeler B, Dudler J, Bernhard J, Exer P, Scherer A, Rheumatologists of the Swiss Clinical Quality Management Program for Axial Spondyloarthritis. Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheum 2013; 65:3096-106.
01.12.2013Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort
01.12.2013Arthritis Rheum 2013; 65:3096-106
Ciurea Adrian, Weber Ulrich, Boonen Annelies, Dougados Maxime, van der Heijde Désirée, Michel Beat A, Nissen Michael J, Müller Rüdiger, Weiss Bettina, Tamborrini Giorgio, Rufibach Kaspar, Stekhoven Daniel, Kissling Rudolf, Beyeler Brigitte, Dudler Jean, Bernhard Jürg, Exer Pascale, Scherer Almut, Rheumatologists of the Swiss Clinical Quality Management Program for Axial Spondyloarthritis
Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletion
Walker U, Courvoisier D, Dudler J, Aeberli D, von Kempis J, Scherer A, Finckh A, Swiss Clinical Quality Management Programme in Rheumatic Diseases. Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletion. Rheumatology (Oxford) 2010; 50:243-4.
17.08.2010Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletion
17.08.2010Rheumatology (Oxford) 2010; 50:243-4
Walker Ulrich A, Courvoisier Delphine S, Dudler Jean, Aeberli Daniel, von Kempis Johannes, Scherer Almut, Finckh Axel, Swiss Clinical Quality Management Programme in Rheumatic Diseases